Possibilities of achieving control of allergic rhinitis in a patient with skin sensitization and continued contact with pets

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Skin sensitization is becoming an increasingly common pathology among year-round allergies, and its clinical manifestations vary in patients from the discomfort caused by rhinoconjunctivitis to severe bronchial asthma which can have a huge negative impact on the patient’s quality of life. One of the important recommendations when identifying sensitization to epidermal allergens is complete elimination, but in routine practice this recommendation is not followed in most cases due to the inability to part with the animal. Thus, exposure to the allergen persists and the symptoms continue to bother and progress.

The article presents a clinical case of achieving control of allergic rhinitis in a patient with skin sensitization and ongoing contact with pets demonstrating successful experience with the use of a fixed combination of olopatadine and mometasone over a long period of observation.

About the authors

Darya S. Kulichenko

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia

Author for correspondence.
Email: darya.mdinaradze@yandex.ru
ORCID iD: 0000-0002-7375-1759
SPIN-code: 2036-0430
Russian Federation, Moscow

Ksenia S. Pavlova

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia

Email: ksenimedical@gmail.com
ORCID iD: 0000-0002-4164-4094
SPIN-code: 7593-0838

D, Cand. Sci. (Medicine)

Russian Federation, Moscow

Oksana M. Kurbacheva

National Research Center — Institute of Immunology Federal Medical-Biological Agency of Russia; ROSUNIMED

Email: kurbacheva@gmail.com
ORCID iD: 0000-0003-3250-0694
SPIN-code: 5698-6436

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow; Moscow

References

  1. Survey: Almost half of Russian families have pets [electronic resource]. Мoscow, 2019. Available from: https://tass.ru/obschestvo/7168177. Accessed: 19.11.2024.
  2. Bass E.A. The role of exposure to the main cat allergens (FEL D 1, FEL D 2, FEL D 4) in the sensitizing profile and severity of rhinitis in children. Dis. … candidate of medical sciences. Ekaterinburg, 2019.
  3. Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733–743. doi: 10.1016/s0140-6736(06)69283-0
  4. Konradsen JR, Fujisawa T, van Hage M, et al. Allergy to furry animals: new insights, diagnostic approaches, and challenges. J Allergy Clin Immunol. 2015;135(3): 616–625. doi: 10.1016/j.jaci.2014.11.008
  5. Allergic rhinitis. Clinical guidelines. Russian Association of Allergists and Clinical Immunologists; National Medical Association of Otorhinolaryngologists; Union of Pediatricians of Russia. 2024.
  6. Segall N, Prenner B, Lumry W, et al. Long-term safety and efficacy of olopatadine-mometasone combination nasal spray in patients with perennial allergic rhinitis. Allergy Asthma Proc. 2019;40(5):301–310. doi: 10.2500/aap2019.s19-0003
  7. Bousquet J, Schünemann HJ, Togias A, et al. Next-generation Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol. 2020;145(1):70–80.e3. doi: 10.1016/j.jaci.2019.12.001
  8. Gross GN, Berman G, Amar NJ, et al. Efficacy and safety of olopatadine-mometasone combination nasal spray for the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2019;122(6):630–638.e3. doi: 10.1016/j.anai.2019.03.017
  9. Hampel FC, Pedinoff AJ, Jacobs RL, et al. Olopatadine-mometasone combination nasal spray: evaluation of efficacy and safety in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2019;40(4):261–272. doi: 10.2500/aap2019.s19-0002
  10. Meltzer EO, Wallace D, Dykewicz M, Shneyer L. Minimal clinically important Difference (MCID) in allergic rhinitis: agency for healthcare research and quality or anchor-based thresholds? J Allergy Clin Immunol Pract. 2016;4(4):682–688.e6. doi: 10.1016/j.jaip.2016.02.008
  11. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21(1):77–83. doi: 10.1111/j.1365-2222.1991.tb02478

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Dynamics of evaluation of the results of the Rhinoconjunctivitis Quality of Life Questionnaire in a patent during therapy with a fixed combination of mometasone + olopatadine 25/600 µg.

Download (202KB)
Indexing metadata

Copyright (c) 2025 PH “ABV-Press”

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).